<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7498210\results\search\drug\results.xml">
  <result pre="currently become pandemic worldwide. Though drugs like remdesivir, favipiravir, and" exact="dexamethasone" post="found beneficial for COVID-19 management, they have limitations clinically,"/>
  <result pre="hydrophobic, electrostatic interactions. The drugs such as arbutin, terbutaline, barnidipine," exact="tipiracil" post="and aprepitant identified as potential hits. Among the drugs,"/>
  <result pre="interactions. The drugs such as arbutin, terbutaline, barnidipine, tipiracil and" exact="aprepitant" post="identified as potential hits. Among the drugs, tipiracil and"/>
  <result pre="tipiracil and aprepitant identified as potential hits. Among the drugs," exact="tipiracil" post="and aprepitant interacted with the Mpro consistently, and they"/>
  <result pre="aprepitant identified as potential hits. Among the drugs, tipiracil and" exact="aprepitant" post="interacted with the Mpro consistently, and they turned out"/>
  <result pre="repurposing using computer-aided docking tools and the potential roles of" exact="tipiracil" post="and aprepitant, which can be explored further in the"/>
  <result pre="and visual interpretations, the drugs aprepitant, barnidipine, tipiracil, arbutin, and" exact="terbutaline" post="were found to be significantly interacting with Mpro residues"/>
  <result pre="Molecular interactions H-bond-forming interactions Ï€-Ï€ stacking or Ï€-cation interaction 1" exact="Aprepitant" post="Chemotherapy-induced emesis, Postoperative nausea and vomiting âˆ’6.892 - HIE41"/>
  <result pre="HIE41 4 Arbutin Skin-lightening agent, Hyperpigmentation âˆ’6.206 ASN142(2) HIE41 5" exact="Terbutaline" post="Asthma, Wheezing, COPD âˆ’5.846 GLY143, HIS164, GLN189 HIE41 Residues"/>
  <result pre="GLU: Glutamic acid; HIS: Histidine; GLY: Glycine; GLN: Glutamine; HIE:" exact="Histidine" post="(HISÎ­). The drug aprepitant made a Ï€-Ï€ stacking interaction"/>
  <result pre="Histidine; GLY: Glycine; GLN: Glutamine; HIE: Histidine (HISÎ­). The drug" exact="aprepitant" post="made a Ï€-Ï€ stacking interaction with histidine (HIE41) residue"/>
  <result pre="stacking interaction with histidine (HIE41) residue of Mpro. The drug" exact="barnidipine" post="made hydrogen bonding interactions with aspargine (ASN142), cysteine (CYS145),"/>
  <result pre="stacking interaction with HIE41, two hydrogen bonding interaction with ASN142." exact="Terbutaline" post="exhibited hydrogen bonding interactions with glycine (GLY143), HIS164 and"/>
  <result pre="bonding interaction with ASN142. Terbutaline exhibited hydrogen bonding interactions with" exact="glycine" post="(GLY143), HIS164 and glutamine (GLN189) residues of Mpro a"/>
  <result pre="MD-simulation exhibited strong and stable binding with Mpro for the" exact="aprepitant" post="and tipiracil where the RMSD-fluctuations for the ligand and"/>
  <result pre="strong and stable binding with Mpro for the aprepitant and" exact="tipiracil" post="where the RMSD-fluctuations for the ligand and protein remained"/>
  <result pre="for the ligand and protein remained within 2.0Â Ã…. The" exact="barnidipine" post="and terbutaline demonstrated strong binding ability and arbutin demonstrated"/>
  <result pre="ligand and protein remained within 2.0Â Ã…. The barnidipine and" exact="terbutaline" post="demonstrated strong binding ability and arbutin demonstrated the least"/>
  <result pre="protein backbone fluctuations; red colour represents ligand fluctuations. The Mpro-bound" exact="aprepitant" post="exhibited good binding mode during MD-simulation. The plot of"/>
  <result pre="the simulation (FigureÂ 2 ). FigureÂ 2 Interaction diagram of" exact="aprepitant" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
  <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="aprepitant" post="with residues in each trajectory frame. The darker colour"/>
  <result pre="higher the interaction or the residues make more contact; (C)" exact="Aprepitant" post="interaction with the protein residues during MD simulation. Interactions"/>
  <result pre="residue (41%) (FigureÂ 3 ). FigureÂ 3 Interaction diagram of" exact="barnidipine" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
  <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="barnidipine" post="with residues in each trajectory frame. The darker colour"/>
  <result pre="acid residue (FigureÂ 4 ). FigureÂ 4 Interaction diagram of" exact="tipiracil" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
  <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="tipiracil" post="with residues in each trajectory frame. The darker colour"/>
  <result pre="shown are occurring more than 30% during the simulation time." exact="Terbutaline" post="bound to Mpro exhibited polar as well as non-polar"/>
  <result pre="This indicates that the ligand-protein complex was unstable compared to" exact="tipiracil" post="and aprepitant. A bridged hydrogen bonding was observed with"/>
  <result pre="acid residue (FigureÂ 6 ). FigureÂ 6 Interaction diagram of" exact="terbutaline" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
  <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="terbutaline" post="with residues in each trajectory frame. The darker colour"/>
  <result pre="higher the interaction or the residues make more contact; (C)" exact="Terbutaline" post="interaction with the protein residues during MD simulation. Interactions"/>
  <result pre="first time reported by us for targeting Mpro. The drug" exact="aprepitant" post="is used as an antiemetic in chemotherapy-induced emesis and"/>
  <result pre="an antiemetic in chemotherapy-induced emesis and post operatives emesis (25)." exact="Aprepitant" post="is an antagonist of Neurokinin 1 receptor (NK-1R), it"/>
  <result pre="adjuvant therapy with anti-HIV drugs (26). In the current studies," exact="aprepitant" post="is found a better drug based on its results"/>
  <result pre="screened for inhibiting replication of SARS-CoV-2 in COVID-19. The drug" exact="tipiracil" post="is currently used along with an anticancer agent trifluridine"/>
  <result pre="agent trifluridine at the cite of action. At therapeutic doses," exact="tipiracil" post="has no reported adverse events (28). In this study,"/>
  <result pre="events (28). In this study, the data infers that the" exact="tipiracil" post="interaction with Mpro is much more durable and stable"/>
  <result pre="both SP-docking and molecular dynamics simulations. Thus, the repurposing of" exact="tipiracil" post="will have advantages compared to other selected molecules. The"/>
  <result pre="be repurposed to treat COVID-19 if explored further. The drug" exact="terbutaline" post="sometimes used to prevent premature labour, is also the"/>
  <result pre="asthma, wheezing and COPD (31). Because of its lung specificity," exact="terbutaline" post="will have advantages if it is found useful in"/>
  <result pre="and favipiravir have been officially approved for COVID-19 treatment. Similarly," exact="dexamethasone" post="is an immunosuppressant is repurposed for COVID-19 to reduce"/>
  <result pre="and whereby reduce the mortality. The anti-HIV drugs such as" exact="ritonavir" post="and nelfinavir, have been proposed for repurposing in COVID-19"/>
  <result pre="Mpro (32). The antiviral drugs such as solutegravir, raltegravir, paritaprevir," exact="bictegravir" post="and dolutegravir were also suggested in another report (33)."/>
  <result pre="in another report (33). Similarly, anti-hepatitis-C virus drugs paritaprevir and" exact="simeprevir" post="was suggested in another report as a covalent inhibitor"/>
  <result pre="In another study, drugs such as simeprevir, ergotamine, bromocriptine and" exact="tadalafil" post="are proposed by the researcher (35). There was a"/>
  <result pre="virtual screening report on peptides drugs such as nafarelin and" exact="icatibant" post="for repurposing to COVD-19 (36). Similarly, the drugs leupeptin,"/>
  <result pre="aprepitant, barnidipine, tipiracil, arbutin and terbutaline. Among these five drug-hits," exact="aprepitant" post="and tipiracil were found strongest in binding Mpro by"/>
  <result pre="tipiracil, arbutin and terbutaline. Among these five drug-hits, aprepitant and" exact="tipiracil" post="were found strongest in binding Mpro by MD-simulation studies."/>
  <result pre="tools and shortlisted five drugs. Further, testing theses drugs, especially" exact="aprepitant" post="and tipiracil, by inÂ vitro Mpro inhibitory activity and"/>
  <result pre="of nausea and vomitingDrugs6920091853187819719336 26BarrettJ.S.SpitsinS.MoorthyG.Pharmacologic rationale for the NK1R antagonist," exact="aprepitant" post="as adjunctive therapy in HIVJ Transl Med14201614827230663 27SakaiT.TeramuraT.OkamiyaH.A review"/>
 </snippets>
</snippetsTree>
